Skip to main content
Clinical Trials/NCT04866888
NCT04866888
Recruiting
Not Applicable

Short and Intermediate Term Outcomes of Uterine Conservation After Cesarian Section in Cases of Placenta Accreta Spectrum

Alexandria University1 site in 1 country120 target enrollmentApril 28, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Placenta Accreta Spectrum
Sponsor
Alexandria University
Enrollment
120
Locations
1
Primary Endpoint
abnormal uterine bleeding
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

study will be carried out on patients with placenta accreta spectrum having done uterine conservation and recording immediate outcome of conservation regarding success of the procedure, amount of blood loss and amount of blood transfused and followed up to check the return of menses, any uterine abnormalities by ultrasound or hysteroscopy especially isthmocele and intrauterine synechia.

Detailed Description

After institutional review board approval and written informed consent, recruited cases will be subjected to the following: 1. Data registration including: * Age. * Obstetric history including gravidity, parity, number of previous cesarean deliveries, and number and gender of living children. * Details of the current pregnancy including duration in menstrual weeks, any problems encountered during its course. * Desire for future fertility. * Medical, surgical, and medication history. 2. Anthropometry including weight, height, and body mass index (BMI) before pregnancy and at the time of operation. 3. General examination including vital signs, and signs of any associated problems. 4. Routine laboratory investigations with particular emphasis on complete blood count, Coagulation profile and including blood glucose level, renal and liver function tests. 5. Detailed sonographic examination to evaluate fetal biometry, and wellbeing rule out exclusion factors, and confirm diagnosis of PAS and assess the degree of invasion, and its severity using both trans-abdominal transducer with frequency of 2-5 megahertz (MHZ) and trans-vaginal transducer with frequency of 4-10 MHZ. Intraoperative details will be documented. Follow up of patients will be recorded. Sample size was calculated by estimating a single proportion distribution at a significance level of 0.05.

Registry
clinicaltrials.gov
Start Date
April 28, 2021
End Date
March 15, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • • Diagnosed sonographically to have placenta accreta spectrum.
  • Pregnancy is singleton and fetus is alive.
  • Elective caesarean section done from 35 gestational weeks.

Exclusion Criteria

  • • Patients requesting hysterectomy.
  • Coexisting uterine pathology such as fibroids or gynaecological malignancies.
  • Patients with bleeding diathesis.
  • Morbid obesity of BMI \>
  • Patients having labour pains or vaginal bleeding before scheduled intervention.

Outcomes

Primary Outcomes

abnormal uterine bleeding

Time Frame: from 2 to 6 months after surgery

record the presence of abnormal uterine bleeding after the return of menses such as intermenstrual bleeding, menorrhagia

isthmocele

Time Frame: from 3 to 6 months after surgery

trans-vaginal and trans-abdominal ultrasound will be done to record the presence of isthmocele, its shape and ratio between residual myometrium and total myometrium

date of resumed menses

Time Frame: from 2 weeks to 6 months after surgery

calculate the duration from surgery until menses returns

puerperal blood loss

Time Frame: 48 hours until 2 months after surgery

recording the duration of blood loss during puerperium and average number of tampons changed per day

menstrual abnormalities

Time Frame: from 2 to 6 months after surgery

record type of menstrual abnormalities if present such as amenorrhea, oligomenorrhea and dysmenorrhea

pelvic pain

Time Frame: from 2 to 6 months after surgery

record the presence of pelvic pain and its duration

intrauterine adhesions

Time Frame: from 3 to 6 months after surgery

outpatient hysteroscopy will be done to symptomatic patients after consent in order to check uterine cavity recording the presence of intrauterine adhesions, and categorization of adhesions according to american fertility society into mild, moderate and severe

contraception use

Time Frame: intraoperative until 5 months after surgery

recording method of contraception used

fibrosis

Time Frame: from 3 to 6 months after surgery

grey scale ultrasound will be done to record size of intra-myometrium fibrosis

Secondary Outcomes

  • packed red blood cells transfusion(intraoperative until 24 hours after surgery)
  • fresh frozen plasma (FFP) transfusion(intraoperative until 24 hours postoperative)
  • post-operative hemoglobin(postoperative within 6 hours from surgery)
  • ureter injury(intraoperative until 2 weeks post operative)
  • surgical site infection(24 hours until 1 month after surgery)
  • hospital stay(postoperative until 10 days after surgery)
  • ICU admission(immediate postoperative until 5 days after surgery)
  • pre-operative hemoglobin(preoperative)
  • intermediate care admission(recording the number of patients admitted to the ICU)
  • operation time(intraoperative)
  • repair time(intraoperative)
  • bowel injury(intraoperative until 2 weeks post operative)
  • Estimated blood loss(intraoperative)
  • bladder injury(intraoperative until 2 weeks post operative)
  • urine output(intraoperative)
  • internal iliac artery ligation(intraoperative)
  • surgical diagnosis(intraoperative)

Study Sites (1)

Loading locations...

Similar Trials